Full Paper

Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals

  1. Jie Lu1,
  2. Monty Liong2,
  3. Zongxi Li2,
  4. Jeffrey I. Zink2,
  5. Fuyuhiko Tamanoi1,*

Article first published online: 7 JUL 2010

DOI: 10.1002/smll.201000538

Issue

Small

Small

Volume 6, Issue 16, pages 1794–1805, August 16 2010

Additional Information

How to Cite

Lu, J., Liong, M., Li, Z., Zink, J. I. and Tamanoi, F. (2010), Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. Small, 6: 1794–1805. doi: 10.1002/smll.201000538

Author Information

  1. 1

    California NanoSystems Institute, Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)

  2. 2

    California NanoSystems Institute, Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA)

*California NanoSystems Institute, Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095 (USA).

Publication History

  1. Issue published online: 12 AUG 2010
  2. Article first published online: 7 JUL 2010
  3. Manuscript Received: 3 APR 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (1420K)

Keywords:

  • animal model;
  • biocompatibility;
  • biodistribution;
  • mesoporous silica nanoparticles;
  • tumor suppression

Abstract

Mesoporous silica nanoparticles (MSNs) are a promising material for drug delivery. In this Full Paper, MSNs are first shown to be well tolerated, as demonstrated by serological, hematological, and histopathological examinations of blood samples and mouse tissues after MSN injection. Biodistribution studies using human cancer xenografts are carried out with in vivo imaging and fluorescent microscopy imaging, as well as with inductively coupled plasma mass spectroscopy. The results show that MSNs preferentially accumulate in tumors. Finally, the drug-delivery capability of MSNs is demonstrated by following tumor growth in mice treated with camptothecin-loaded MSNs. These results indicate that MSNs are biocompatible, preferentially accumulate in tumors, and effectively deliver drugs to the tumors and suppress tumor growth.

View Full Article with Supporting Information (HTML) Get PDF (1420K)